Prelude Therapeutics PRLD
NASDAQ PRLD
$3.68 +0.15 (+4.25%)
As of: Oct 21, 2026 · 1:52 PM EDT

Prelude Therapeutics (PRLD) Long-Term Debt Repayments (2019 - 2025)

Updated

Prelude Therapeutics' Long-Term Debt Repayments came in at $208,000 for FY2025, down 47.3% from $395,000 in FY2024.

Analysis

Prelude Therapeutics (PRLD) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends

Going back to FY2019, Prelude Therapeutics' Long-Term Debt Repayments data covers 4 years.

  • Long-Term Debt Repayments carries a five-year compound annual growth rate of -4.2% (FY2020 to FY2025).
  • The FY2025 figure represents the lowest annual Long-Term Debt Repayments since FY2019.
  • Per Business Quant, earlier years put Long-Term Debt Repayments at $395,000 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,134.24 Bn 1,102.83 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 616.05 Bn 534.58 Bn 17.26 Bn 1.00 Mn
3 AbbVie 500.90 Bn 474.01 Bn 12.70 Bn 2.00 Bn
4 Merck 367.17 Bn 321.54 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn 2.46 Bn
7 Amgen 235.77 Bn 191.17 Bn 7.24 Bn -
8 Gilead Sciences 190.70 Bn 164.90 Bn 6.22 Bn 17.00 Mn
9 Pfizer 169.35 Bn 115.99 Bn 10.94 Bn -
10 Prelude Therapeutics 361.09 Mn -236.21 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 53,000.00
Mar 31, 2025 155,000.00
Dec 31, 2024 151,000.00
Sep 30, 2024 148,000.00
Sep 30, 2020 67,000.00
Jun 30, 2020 96,000.00
Mar 31, 2020 95,000.00
Dec 31, 2019 93,000.00
API Access

Prelude Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=PRLD&period=max&api_key=YOUR_API_KEY